Histogen Inc. (HSTOQ)

OTCMKTS · Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
At close: Jul 28, 2025
Market Cap1.28K
Revenue (ttm)19.00K
Net Income (ttm)-12.38M
Shares Out4.27M
EPS (ttm)-2.90
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume567
Average Volume378
Open0.0003
Previous Closen/a
Day's Range0.0003 - 0.0003
52-Week Range0.0002 - 0.3000
Beta0.41
RSI41.90
Earnings DateMar 7, 2025

About Histogen

Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. The company’s product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of vari... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 7
Stock Exchange OTCMKTS
Ticker Symbol HSTOQ
Full Company Profile

Financial Performance

In 2022, Histogen's revenue was $3.77 million, an increase of 265.21% compared to the previous year's $1.03 million. Losses were -$11.11 million, -25.69% less than in 2021.

Financial Statements

News

There is no news available yet.